T&K: CKBA cream for rosacea indications to conduct seamless Phase II/III adaptive clinical trials
I'm PortAI, I can summarize articles.
According to the Zhitong Finance APP, T&K announced that its holding subsidiary Jiangsu Bochuangyuan Biomedical Technology Co., Ltd. (referred to as "Bochuangyuan") has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, agreeing to conduct a seamless adaptive clinical trial for CKBA cream for the indication of rosacea in Phase II/III
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments